Sumitomo Pharma Co Ltd 2019 Integrated Report
The report outlines Sumitomo Dainippon Pharma's corporate strategy, financial performance, and sustainability initiatives for fiscal 2018 (ended March 31, 2019). The company established its Mid-term Business Plan 2022 and Vision 2033 to become a Global Specialized Player. It highlights progress in its core focus areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine/Cell Therapy. In ESG initiatives, the company updated its materiality matrix, set CO2 reduction targets aiming for SBT certification, and achieved 10.7% female managerial staff.
Company: Sumitomo Pharma Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2019
Type: Integrated Report
Pages: 130
Back to company
Sumitomo Pharma Co Ltd
Integrated Report
The report outlines Sumitomo Dainippon Pharma's corporate strategy, financial performance, and sustainability initiatives for fiscal 2018 (ended March 31, 2019). The company established its Mid-term Business Plan 2022 and Vision 2033 to become a Global Specialized Player. It highlights progress in its core focus areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine/Cell Therapy. In ESG initiatives, the company updated its materiality matrix, set CO2 reduction targets aiming for SBT certification, and achieved 10.7% female managerial staff.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2018
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Total Waste
Women on Board
Women in Management
Employees